Mazdutide
Mazdutide (IBI362)
Overview
Mazdutide (IBI362) is a dual GLP-1 and glucagon receptor co-agonist developed by Innovent Biologics that has completed Phase 2 trials in China showing significant weight loss and metabolic improvements. It represents a different approach to dual receptor agonism from tirzepatide — combining GLP-1 with glucagon rather than GLP-1 with GIP. The glucagon component drives enhanced energy expenditure and fat oxidation complementing GLP-1's appetite suppression for a metabolically distinct profile.
Mechanism of Action
Mazdutide activates both GLP-1 receptors and glucagon receptors with balanced agonism. GLP-1 receptor activation provides the established benefits of incretin signaling — insulin secretion glucagon suppression gastric emptying delay and appetite reduction. Glucagon receptor activation adds direct hepatic effects including increased fat oxidation gluconeogenesis stimulation and thermogenesis. The glucagon component's thermogenic effects are particularly valuable — increasing basal metabolic rate means weight loss occurs through both caloric restriction and increased energy expenditure simultaneously. This dual mechanism has shown favorable effects on liver fat content making it particularly interesting for non-alcoholic fatty liver disease (NAFLD) applications beyond obesity.
Dosage Information
Typical Dose
3-9 mg weekly (Phase 2 trial doses)
Frequency
Once weekly
Administration
Subcutaneous injection
Notes
Phase 2 completed in China. International Phase 3 development ongoing. Not yet approved outside of China. Entry documents research context.
Where does Mazdutide sit?
See how this peptide compares across all 111 peptides in our database.
Evidence Score
0.71
Compound Data
Molecular Formula
C207H317N45O65
Molecular Weight
4476.00 g/mol
IUPAC Name
20-[[(1S)-4-[2-[2-[2-[2-[2-[2-[[(5S)-5-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-5-amino-2-[[2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]-2-methylpropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-4-carboxybutanoyl]amino]hexanoyl]amino]hexanoyl]amino]propanoyl]amino]-6-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[2-[(2S)-2-[[(2S)-1-[(2-amino-2-oxoethyl)amino]-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-2-oxoethyl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-6-oxohexyl]amino]-2-oxoethoxy]ethoxy]ethylamino]-2-oxoethoxy]ethoxy]ethylamino]-1-carboxy-4-oxobutyl]amino]-20-oxoicosanoic acid
PubChem CID
167312357Potential Side Effects
Community Experiences
No experiences shared yet. Be the first!
Quick Facts
- Administration
- Subcutaneous injection
- Typical Dose
- 3-9 mg weekly (Phase 2 trial doses)
- Frequency
- Once weekly
- References
- 0 curated + 19 from PubMed
- Clinical Trials
- 20 registered
- Evidence Score
- 0.7 / 100